48 Participants Needed

BGB-43395 for Healthy Subjects

SD
Overseen ByStudy Director Study Director
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: BeiGene
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. However, since the trial is for healthy participants, it's possible that taking medications could affect eligibility. Please consult with the trial organizers for more details.

What is the purpose of this trial?

Study to determine the relative bioavailability of BGB-43395 solid dispersion tablet compared to salt tablet in healthy adult participants in Part 1 and the effect of food on the selected BGB-43395 formulation solid dispersion tablet or salt tablet in healthy adult participants in Part 2.

Research Team

SD

Study Director Study Director

Principal Investigator

BeiGene

Eligibility Criteria

This trial is for healthy adults aged 18-65 with a BMI between 18.0 and 32.0 kg/m2. Participants must be in good health without significant medical history findings and willing to follow study rules.

Inclusion Criteria

Body mass index between 18.0 and 32.0 kg/m2, inclusive
In good health, as determined by no clinically significant findings from medical history
Able to comprehend and are willing to sign the ICF and abide by the study restrictions

Exclusion Criteria

History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator or designee
Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute. If any parameter is out of range, measurements should be repeated twice. Participants will be excluded if the average of the 3 measurements are outside of the corresponding reference range
History of prolonged QT interval/QT interval corrected for heart rate, with QTcF >450 ms for males and >470 ms for females
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part 1

Participants receive a single dose of each formulation of BGB-43395 in separate periods to determine relative bioavailability

4 weeks
Multiple visits (in-person)

Treatment Part 2

Participants receive three doses of the selected formulation of BGB-43395 under different dietary conditions to assess food effect

4 weeks
Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • BGB-43395
Trial Overview The study tests two forms of BGB-43395 (solid dispersion tablet vs salt tablet) for absorption in the body, and how food affects its absorption.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Part 2: Food EffectExperimental Treatment1 Intervention
Participants will receive three doses of the selected formulation of BGB-43395 under fasted, low-fat, or high-fat conditions in separate periods across various sequences.
Group II: Part 1: Relative BioavailabilityExperimental Treatment1 Intervention
Participants will receive a single dose of each formulation of BGB-43395 in separate periods across various sequences.

Find a Clinic Near You

Who Is Running the Clinical Trial?

BeiGene

Lead Sponsor

Trials
216
Recruited
32,500+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security